Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
pneumococcal 23v polysaccharide vaccine · 1 trial · 1 indication
Blood drawn at Day 1 and Day 30 of the extension study were used to measure IgG antibody levels to 8 pneumococcal polysaccharide serotypes (3, 4, 6B,8, 9V, 12F, 14, 23F) by ELISA.
Blood drawn at Day 1 and Day 30 of the extension study were used to measure IgG antibody levels to 8 pneumococcal polysaccharide serotypes (3, 4, 6B, 8, 9V, 12F, 14, 23F) by ELISA.
Blood drawn at Day 1 and Day 30 of the extension study were used to measure IgG antibody levels to 8 pneumococcal polysaccharide serotypes (3, 4, 6B, 8, 9V, 12F, 14, 23F) by ELISA.
Blood drawn at Day 1 and Day 30 of the extension study were used to measure IgG antibody levels to 8 pneumococcal polysaccharide serotypes (3, 4, 6B, 8, 9V, 12F, 14, 23F) by ELISA.
Blood drawn at Day 1 and Day 30 of the extension study were used to measure IgG antibody levels to 8 pneumococcal polysaccharide serotypes (3, 4, 6B, 8, 9V, 12F, 14, 23F) by ELISA.
Blood drawn at Day 1 and Day 30 of the extension study were used to measure IgG antibody levels to 8 pneumococcal polysaccharide serotypes (3, 4, 6B, 8, 9V, 12F, 14, 23F) by ELISA.
Blood drawn at Day 1 and Day 30 of the extension study were used to measure IgG antibody levels to 8 pneumococcal polysaccharide serotypes (3, 4, 6B, 8, 9V, 12F, 14, 23F) by ELISA.
Blood drawn at Day 1 and Day 30 of the extension study were used to measure IgG antibody levels to 8 pneumococcal polysaccharide serotypes (3, 4, 6B, 8, 9V, 12F, 14, 23F) by ELISA.
| Arm | Type | Description |
|---|---|---|
| 1st Revaccination Group | EXPERIMENTAL | - |
| 2nd Revaccination Group | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| pneumococcal 23v polysaccharide vaccine | BIOLOGICAL | Duration of Treatment: Single vaccination on Day 1 |
Inclusion Criteria: * Postmenopausal or negative urine pregnancy test if female * No fever on the day of vaccination Exclusion Criteria: * History of allergy to vaccine components * History of pneumococcal disease * Received any live virus vaccination within 4 weeks prior to study start * Receive...
Pneumococcal 23v polysaccharide vaccine is used for the prevention of pneumococcal infection, a disease caused by the bacterium Streptococcus pneumoniae. It is a vaccine that helps the immune system recognize and fight the bacteria, reducing the risk of serious infections such as pneumonia, bacteremia, and meningitis.
Pneumococcal 23v polysaccharide vaccine is developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. Merck is responsible for the research, development, and potential commercialization of this vaccine.
Pneumococcal 23v polysaccharide vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not yet been approved by regulatory authorities. The Phase 3 trial is designed to evaluate the vaccine's safety and immunogenicity in older adults.
Pneumococcal 23v polysaccharide vaccine has one completed Phase 3 clinical trial, identified by the National Clinical Trial number NCT00560950. This trial, titled "Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)," enrolled 143 participants aged 59 years and older to study revaccination with the vaccine.
Yes, pneumococcal 23v polysaccharide vaccine is the same as PNEUMOVAX 23. The clinical trial NCT00560950 refers to the vaccine as PNEUMOVAX(TM) 23, which is the brand name for this pneumococcal polysaccharide vaccine developed by Merck.